Comparative Pharmacology
Head-to-head clinical analysis: LATANOPROST versus LATISSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LATANOPROST versus LATISSE.
LATANOPROST vs LATISSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Latanoprost is a prostaglandin F2α analogue that acts as a selective FP receptor agonist. It increases uveoscleral outflow of aqueous humor by binding to prostanoid FP receptors in the ciliary muscle, leading to matrix metalloproteinase activation and remodeling of the extracellular matrix, thereby reducing intraocular pressure.
Bimatoprost is a synthetic prostamide analog that selectively mimics the effects of prostamide F2α. It increases the growth of eyelashes by prolonging the anagen (growth) phase and increasing the number of hairs. The exact molecular mechanism is thought to involve binding to prostamide receptors, leading to modulation of intracellular signaling pathways that regulate hair follicle cycling.
Instill one drop (1.5 mcg) of 0.005% ophthalmic solution into the affected eye(s) once daily in the evening.
One drop applied to the upper eyelid margin at the base of the eyelashes once daily using the provided sterile applicators.
None Documented
None Documented
Clinical Note
moderateLatanoprost + Unoprostone
"Latanoprost may increase the hypotensive activities of Unoprostone."
Clinical Note
moderateLatanoprost + Hydrochlorothiazide
"Latanoprost may increase the hypotensive activities of Hydrochlorothiazide."
Clinical Note
moderateTiaprofenic acid + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Latanoprostene bunod
Terminal half-life of latanoprost acid is 17 minutes (0.28 hours) systemically; clinically, intraocular pressure reduction persists for 24 hours due to prolonged receptor binding.
The terminal elimination half-life of bimatoprost in plasma is approximately 45 minutes (range 30-60 minutes) after topical ocular application in humans. This short half-life reflects rapid systemic clearance, but the drug's ocular hypotensive effect persists for 24 hours due to tissue binding.
Renal: 88% (metabolites); fecal: 6% (metabolites); unchanged latanoprost is not excreted renally.
Primarily renal elimination of metabolites; less than 5% of unchanged bimatoprost is excreted in urine. Fecal excretion accounts for approximately 25% of the dose, predominantly as metabolites. Biliary excretion is minimal.
Category A/B
Category C
Prostaglandin Analog
Prostaglandin Analog
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Carprofen."